December 14, 2022
Despite a challenging economic climate in the latter half of 2022, the year was marked by major milestones in psychedelic
December 7, 2022
UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows
November 30, 2022
On Tuesday, 29 November, PSYCH released the fourth edition of The Psychedelics as Medicine Report. The report, expanded to include
November 23, 2022
Veteran affairs receive bipartisan support across North America, with public opinion prompting lawmakers and regulators to support innovations in veteran
November 15, 2022
Tomorrow, Thursday, 17 November, industry leaders will meet in London for Emerging Innovations in Psychedelic Healthcare, to evaluate milestones in
November 7, 2022
Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Policy Reform Group (CDPRG) representative, Crispin Blunt
November 2, 2022
Psychedelic medicines are entering the latter stages of drug development, progressing from Phase II to Phase III trials, with the
October 26, 2022
It is a pivotal time for Small Pharma, as it anticipates data from its Phase IIa trial with lead candidate
October 19, 2022
In March, the Washington State legislature passed Senate Bill 5660, directing Washington State Health Care Authority to assess the provision
October 12, 2022
For The Psychedelics as Medicine Report: Fourth Edition, PSYCH spoke with Dr Laura Squire, Chief Healthcare Quality and Access Officer
October 5, 2022
On 8 November, over one million people in Colorado voted in favour of the Natural Medicine Health Act, Proposition 122,
September 28, 2022
Psychiatrist Dr Ben Sessa, Head of Psychedelic Medicine at Awakn Life Sciences, specialises in addiction services and psychedelic-assisted therapy. PSYCH
